Aurum Biosciences Ltd is a biopharmaceutical company developing novel oxygen carriers and proprietary software for use with MRI, initially for Acute Ischaemic Stroke (AIS). Follow-on indications include heart disease, cancer, epilepsy, and dementia. Aurum is currently taking a stroke management product (“GOLD”) through preclinical development and into clinical studies of efficacy and safety.
Aurum develops novel pharmaceuticals for use in a number of different clinical indications of high unmet medical need. Aurum is currently completing preclinical development of ABL101, its lead stroke management product, and envisages initiating clinical studies of efficacy and safety in the near future. Follow-on programmes include products for heart disease, cancer, epilepsy, and dementia. Aurum’s lead project utilises an oxygen carrier and proprietary software for use with MRI in Acute Ischaemic Stroke. Aurum has funding in place to initiate recruitment for a Phase 2 clinical study in stroke patients.